ArticleMedicine2017
Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.
Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder.Internal medicine (Tokyo, Japan) · 2026Article
- Systemic Medications and Their Ocular Side Effects.Cureus · 2024Review
- Applications of Biological Therapy for Latent Infections: Benefits and Risks.International journal of molecular sciences · 2024Review
- Effect of HTLV-1 Infection on the Clinical Course of Patients with Rheumatoid Arthritis.Viruses · 2022Review
- Updates on HTLV-1 Uveitis.Viruses · 2022Review
- Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis.Frontiers in microbiology · 2022Article
- Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1.The Journal of international medical research · 2021Article
- Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy.Internal medicine (Tokyo, Japan) · 2020Article
- HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- HTLV-1 Infection and Rheumatic Diseases.Frontiers in microbiology · 2020Review
- Ocular side effects of antirheumatic medications: a qualitative review.BMJ open ophthalmology · 2020Review
- HTLV-1 in Ophthalmology.Frontiers in microbiology · 2020Review
- Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious ConditionsFrontiers in microbiology · 2019Article
- Differential diagnosis of multiple sclerosis in Latin America.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThere are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood. PATIENT CONCERNS AND DIAGNOSIS: An HTLV-1-infected 66-year-old female with HTLV-1 uveitis (HU) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Her HU had been in remission and her HAM/TSP symptoms had been managed effectively with oral steroids for years. However, she developed severe rheumatoid arthritis (RA) after failing to respond well to conventional anti-rheumatic agents.
interventionsShe was administered two intravenous 8mg/kg doses of the biologic tocilizumab. OUTCOMES: Subsequently, her RA symptoms resolved, but she suffered a recurrence of HU and exacerbation of HAM/TSP symptoms. When she was switched back to steroid-based treatment, HU and HAM symptoms both improved, but RA symptoms again worsened. Finally, an attempt to substitute the biologic abatacept and reduce the steroids failed when HAM/TSP symptoms again became aggravated. LESSONS: To the best of our knowledge, this represents the first report worldwide of a biologic aggravating HTLV-1-associated conditions. This report suggests that caution is advised when using biologics to treat HTLV-1-infected patients, though further research is required to clarify the situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.